Suppr超能文献

将抗原工程化为光敏剂纳米载体,以促进活性氧触发的免疫级联反应用于光动力免疫治疗。

Engineering antigen as photosensitiser nanocarrier to facilitate ROS triggered immune cascade for photodynamic immunotherapy.

作者信息

Wang Huaiji, Wang Kun, He Lianghua, Liu Ying, Dong Haiqing, Li Yongyong

机构信息

Shanghai Tenth People's Hospital, The Institute for Biomedical Engineering & Nano Science, Tongji University School of Medicine, Shanghai, 200092, PR China.

Shanghai Tenth People's Hospital, The Institute for Biomedical Engineering & Nano Science, Tongji University School of Medicine, Shanghai, 200092, PR China.

出版信息

Biomaterials. 2020 Jun;244:119964. doi: 10.1016/j.biomaterials.2020.119964. Epub 2020 Mar 16.

Abstract

Despite of the documented immunogenic cell death (ICD) and antigen cross-presentation (AC) in photodynamic therapy (PDT), the overall immune efficacy is rather limited. This study aims to expand the immune potential of PDT by spatially packaging antigen as photosensitiser nanocarrier to trigger efficient immune cascade for photodynamic immunotherapy. The package of ovalbumin antigen (OVA) into sub-100 nm nano-assembly is realized by driving intermolecular disulfide network between OVA molecules. OVA nanoparticles loading photosensitiser Ce6 (ON) are subsequently coated with B16-OVA cancer cell membrane, resulting in membrane cloaked ON (MON). Importantly, laser irradiation generated ROS significantly potentiates OVA antigen cross-presentation efficiency. Whilst, MON is endowed with homophilic targeting towards tumor due to cancer cell membrane coating. In treating B16-OVA tumor-bearing mice, MON effectively triggers the immune cascade, completely eliminates the tumor under laser irradiation and provokes a long-term antitumor immune memory effect. Conversely, a marginal effect is found if substituting OVA for bovine serum protein (BSA) in nanoparticle design or using MON to treat non-OVA expressing tumor. The antigen nanocarrier design promises to complement conventional PDT by boosting immune cascade, thereby leading to unique photodynamic immunotherapy.

摘要

尽管光动力疗法(PDT)中存在已被证实的免疫原性细胞死亡(ICD)和抗原交叉呈递(AC),但其整体免疫疗效相当有限。本研究旨在通过将抗原作为光敏剂纳米载体进行空间包装,以触发高效的免疫级联反应用于光动力免疫治疗,从而扩大PDT的免疫潜力。通过驱动卵清蛋白(OVA)分子间的分子内二硫键网络,实现将OVA抗原包装到100nm以下的纳米组装体中。随后,将负载光敏剂Ce6的OVA纳米颗粒(ON)用B16-OVA癌细胞膜包被,得到膜包被的ON(MON)。重要的是,激光照射产生的活性氧显著增强了OVA抗原交叉呈递效率。同时,由于癌细胞膜包被,MON具有对肿瘤的同源靶向性。在治疗荷B16-OVA肿瘤小鼠时,MON有效触发免疫级联反应,在激光照射下完全消除肿瘤,并激发长期的抗肿瘤免疫记忆效应。相反,如果在纳米颗粒设计中用牛血清蛋白(BSA)替代OVA,或者用MON治疗不表达OVA的肿瘤,则效果甚微。抗原纳米载体设计有望通过增强免疫级联反应来补充传统的PDT,从而带来独特的光动力免疫治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验